280Bio initiates Phase 1 clinical study for YL-17231 after FDA approval
In a significant breakthrough for 280Bio, Inc., a clinical-stage biotechnology company, the US Food and Drug Administration (FDA) has given the green light to its Investigational New Drug (IND) application for YL-17231. This investigational drug, a small molecule inhibitor of RAS signaling, will now proceed to Phase 1 clinical study in the U.S. The RAS […]